The influence of bromelain on platelet count and platelet activity in vitro

Platelets

Volumn 17, Issue 1, 2006, Pages 37-41

  Gläser, Doreen ^a   Hilberg, Thomas ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Aggregometry; Bromelain; CD62P; Platelet activity; Platelet reactivity

Indexed keywords

BROMELAIN; THROMBIN RECEPTOR ACTIVATING PEPTIDE 6;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RECEPTOR BINDING; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT;

ADENOSINE DIPHOSPHATE; ADULT; BLOOD PLATELETS; BROMELAINS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; MALE; P-SELECTIN; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; PLATELET COUNT; REFERENCE VALUES; STIMULATION, CHEMICAL;

ANANAS COMOSUS;

EID: 28744439176     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100500197489     Document Type: Article

References (28)

1. Ota S, Horie K, Hagino F, Hashimoto C, Date H. Fractionation and some properties of the proteolytically active components of bromelains in the stem and the fruit of the pineapple plant. J Biochem (Tokyo) 1972;71:817-830.
2. Yamada F, Takahashi N, Murachi T. Purification and characterization of a proteinase from pineapple fruit, fruit bromelain FA2. J Biochem (Tokyo) 1976;79:1223-1234.
3. Taussig SJ, Batkin S. Bromelain, the enzyme complex of pineapple (Ananas comosus) and its clinical application. An update. J Ethnopharmacol 1988;22:191-203.
4. Lotz-Winter H. On the pharmacology of bromelain: an update with special regard to animal studies on dose-dependent effects. Planta Med 1990;56:249-253.
5. Kelly GS. Bromelain: A literature review and discussion of its therapeutic applications. Altern Med Rev 1996;1:243-257.
6. Leipner J, Iten F, Saller R. Therapy with proteolytic enzymes in rheumatic disorders. BioDrugs 2001;15:779-789.
7. Masson M. Bromelain in blunt injuries of the locomotor system. A study of observed applications in general practice. MMW - Fortschritte der Medizin 1995;113:303-306.
8. Maurer HR. Bromelain: Biochemistry, pharmacology and medical use. Cellular and Molecular Life Sciences 2001;58:1234-1245.
9. Taussig SJ, Nieper HA. Bromelain: Its use in prevention and treatment of cardiovascular disease - Present status. J IAPM 1979;6:139-150.
10. Heinicke RM, van der Wal L, Yokoyama M. Effect of bromelain (Ananase®) on human platelet aggregation. Experientia 1972;28:844-845.
11. Sano T, Yokoyama M. Inhibitory effect of proteolytic enzymes on platelet aggregation induced by ADP or thrombin. Experientia 1971;27:1179-1181.
12. Livio M, De Gaetano G, Donati MB. Effect of bromelain on fibrinogen level, prothrombin complex and platelet aggregation in the rat - A preliminary report. Drugs Exptl Clin Res 1978;4:49-53.
13. Born GVR, Cross MJ. The aggregation of blood platelets. J Physiol 1963;168:178-195.
14. Michelson AD. Flow cytometry: A clinical test of platelet function. Blood 1996;87:4925-4936.
15. Michelson AD, Barnard MR, Krueger LA, Frelinger AL 3rd, Furman MI. Evaluation of platelet function by flow cytometry. Methods 2000;21:259-270.
16. Hilberg T, Eichler E, Glaser D, Schmidt V, Gabriel HH. Platelet activity, reactivity and platelet-leukocyte conjugate formation before and after exhaustive or moderate exercise in patients with IDDM. Platelets 2004;15:101-108.
17. Metzig C, Grabowska E, Eckert K, Rehse K, Maurer HR. Bromelain proteases reduce human platelet aggregation in vitro, adhesion to bovine endothelial cells and thrombus formation in rat vessels in vivo. In Vivo 1999;13:7-12.
18. Hirano K, Kanaide H. Role of protease-activated receptors in the vascular system. J Atheroscler Thromb 2003;10:211-225.
19. Dubois C, Steiner B, Meyer Reigner SC. Contribution of PAR-1, PAR-4 and GPIbalpha in intracellular signaling leading to the cleavage of the beta3 cytoplasmic domain during thrombin-induced platelet aggregation. Thromb Haemost 2004;91:733-742.
20. Kim S, Foster C, Lecchi A, Quinton TM, Prosser DM, Jin J, Cattaneo M, Kunapuli SP. Protease-activated receptors 1 and 4 do not stimulate G(i) signaling pathways in the absence of secreted ADP and cause human platelet aggregation independently of G(i) signaling. Blood 2002;99:3629-3636.
21. Sambrano GR, Weiss EJ, Zheng YW, Huang W, Coughlin SR. Role of thrombin signalling in platelets in haemostasis and thrombosis. Nature 2001;413:74-78.
22. Gachet C, Hechler B, Leon C, Vial C, Leray C, Ohlmann P, Cazenave JP. Activation of ADP receptors and platelet function. Thromb Haemost 1997;78:271-275.
23. Puri RN, Colman RW. ADP-induced platelet activation. Crit Rev Biochem Mol Biol 1997;32:437-502.
24. Pasche B, Ouimet H, Francis S, Loscalzo J. Structural changes in platelet glycoprotein IIb/IIIa by plasmin: determinants and functional consequences. Blood 1994;83:404-414.
25. Ginsberg MH, Frelinger AL, Lam SC, Forsyth J, McMillan R, Plow EF, Shattil SJ. Analysis of platelet aggregation disorders based on flow cytometric analysis of membrane glycoprotein IIb-IIIa with conformation-specific monoclonal antibodies. Blood 1990;76:2017-2023.
26. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307-315.
27. Selnick HG, Barrow JC, Nantermet PG, Connolly TM. Non-peptidic small-molecule antagonists of the human platelet thrombin receptor PAR-1. Curr Med Chem Cardiovasc Hematol Agents 2003;1:47-59.
28. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem 2001;276:4692-4698.